Równocześnie połączenie naproksenu z esomeprazolem zapewnia skuteczną ochronę górnego odcinka przewodu pokarmowego. Przyjmowanie obu substancji czynnych w preparacie złożonym gwarantuje lepsze przestrzeganie schematu leczenia (compliance), podobnie jak w przypadku stosowania preparatów łączonych w leczeniu nadciśnienia tętniczego. Wydaje się, że zastosowanie Na-Es w leczeniu choroby zwyrodnieniowej może być doskonałym przykładem terapii multimodalnej, która zwiększa bezpieczeństwo, a przez to umożliwia dostosowanie farmakoterapii do indywidualnych potrzeb pacjenta. Dostępne obecnie na rynku preparaty łączące NLPZ i PPI, w tym omawiany Na-Es, mogą w najbliższej przyszłości wyznaczać standard postępowania przeciwbólowego w ChZS, z uwzględnieniem redukcji ryzyka działań niepożądanych ze strony górnego odcinka przewodu pokarmowego i układu sercowo-naczyniowego, w szczególności u pacjentów wymagających długotrwałego leczenia.
Artykuł powstał z grantu firmy Bausch Health Poland Sp. z o.o.
Abstract
A new therapeutic option for osteoarthritis
Osteoarthritis is a common disease of the musculoskeletal system that is associated with a constantly increasing incidence. The lack of disease-modifying drugs for osteoarthritis means that the main pillar of pharmacological treatment is currently the use of non-steroidal anti-inflammatory drugs according to the patient’s individual needs and the risk of potential adverse effects. The limitations and difficulties of osteoarthritis therapy can be at least partially resolved with the use of the modern combination of naproxen and esomeprazole (500/20 mg) that has recently become available on the Polish market. The choice of naproxen in this combination is associated with a lower cardiovascular risk as compared to other non-steroidal anti-inflammatory drugs as well as its proven strong analgesic and anti-inflammatory effects. The addition of esomeprazole provides an effective protection of the upper gastrointestinal tract. Taking both active substances in a combination formula helps to significantly improve compliance. It seems that the use of naproxen combined with esomeprazole for treating osteoarthritis can be a good example of a multimodal therapy that increases safety, improves efficacy and allows a better adjustment of pharmacotherapy to the patient’s individual needs.
Piśmiennictwo
1. Steinmetz JD, Culbreth GT, Haile LM, et al. Global, Regional, and National Burden of Osteoarthritis, 1990-2020 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol 2023;5:e508-e522
2. https://stat.gov.pl/files/gfx/portalinformacyjny/pl/defaultaktualnosci/5513/26/1/1/stan_zdrowia_ludnosci_polski_w_2019_r.pdf. Dostęp 06.12.2024
3. Wojcieszek A, Kurowska A, Majda A, et al. The Impact of Chronic Pain, Stiffness and Difficulties in Performing Daily Activities on the Quality of Life of Older Patients with Knee Osteoarthritis. Int J Environ Res Public Health 2022;19:16815
4. Kendzerska T, Juni P, King LK, et al. The Longitudinal Relationship between Hand, Hip and Knee Osteoarthritis and Cardiovascular Events: A Population-Based Cohort Study. Osteoarthr Cartil 2017;25:1771-80
5. Puig-Junoy J, Ruiz Zamora A. Socio-Economic Costs of Osteoarthritis: A Systematic Review of Cost-of-Illness Studies. Semin Arthritis Rheum 2015;44:531-41
6. Giaretta S, Magni A, Migliore A, et al. Review of Current Approaches to Pain Management in Knee Osteoarthritis with a Focus on Italian Clinical Landscape. J Clin Med 2024;13(17):5176
7. Veronese N, Cooper C, Bruyere O, et al. Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs 2022;82:1347
8. Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol 2011;4(5):605-21
9. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101(4):701-10
10. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104(3):728-38
11. https://leki.pl/chpl/e/emoxen-chpl.pdf. Dostęp 06.12.2024
12. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27(6):1243-53
13. Cryer BL, Sostek MB, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med 2011;43(8):594-605
14. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32(3):401-13
15. Sostek MB, Fort JG, Estborn L, et al. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 2011;27(4):847-54
16. Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26(2):265-75
17. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332(7553):1302-5
18. Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet 2013;382:769-79
19. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
20. Nissen SE, Yeomans ND, Solomon DH, et al; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375(26):2519-29
21. Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. Journal of Internal Medicine 2022;292:557-74
22. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85(2):190-7
23. Antman EM, Bennett JS, Daugherty A. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians A Scientific Statement From the American Heart Association. Circulation 2007;115:1634-42
24. Pirlamarla P, Bond RM. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med 2016;26:675-80
25. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76(1):17-28
26. Ho KY, Cardosa MS, Chaiamnuay S, et al. Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. J Pain Res 2020;13:1925-39
27. Minhas D, Nidhaan A, Husni ME. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned? Rheum Dis Clin North Am 2023;49(1):179-91
28. Van Walsem A, Pandhi S, Nixon RM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther 2015;17(1):66. doi: 10.1186/s13075-015-0554-0
29. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA 2018;320(24):2564-79
30. Paglia MDG, Silva MT, Lopes LC, et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One 2021;16(4):e0248866. doi: 10.1371/journal.pone.0248866
31. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis 2020;79(2):276-84
32. Leung GJ, Rainsford KD, Kean WF. Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies. J Pharm Pharmacol 2014;66(3):347-57
33. Bruno R, Iliadis A, Jullien I, et al. Naproxen kinetics in synovial fluid of patients with osteoarthritis. Br J Clin Pharmacol 1988;26(1):41-4
34. Hsueh MF, Bolognesi MP, Wellman SS, et al. Anti-inflammatory effects of naproxen sodium on human osteoarthritis synovial fluid immune cells. Osteoarthritis Cartilage 2020;28(5):639-45
35. Cheleschi S, Pascarelli NA, Valacchi G, et al. Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β. Int Immunopharmacol 2015;28(1):794-801
36. Kocot-Kępska M. Naproksen – multifunkcjonalny niesteroidowy lek przeciwzapalny. Lekarz POZ 2020;6(3):215-20
37. Park MS, Kang CN, Lee WS, et al. A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. PLoS One 2020;15(1):e0226184. doi: 10.1371/journal.pone.0226184
38. Pergolizzi J, Varrassi G, LeQuang JAK, et al. Fixed Dose Versus Loose Dose: Analgesic Combinations. Cureus 2023;15(1):e33320. doi: 10.7759/cureus.33320
39. Brooks PM, Cleland LG, Haski AL, et al. Evaluation of a single daily dose of naproxen in osteoarthritis. Rheumatol Rehabil 1982;21(4):242-6